Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Davoceticept in advanced malignancies
NCT04186637Phase 1Terminated
- Sponsor
- Alpine Immune Sciences, Inc.
- Start
- Jun 2020
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of davoceticept in solid tumor (advanced stage) and lymphoma, sponsored by Alpine Immune Sciences, Inc. Primary endpoint: Adverse Events. Started Jun 2020; status: terminated.
02
Drugs
davoceticept
03
Conditions
solid tumor (advanced stage)lymphoma
Beyond the preview
Go deeper on NCT04186637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04186637.